EXECUTIVE ENGAGEMENTS
POOL
529
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
106
Interactions with Platform & by Email
PARTICIPANTS
21
Unique # Participated
VALIDATIONS
9
Responses Validated*
COMPANIES
38
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
192
EDITION
8
PRICE
USD 4950
CODE
MCP13609
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Nocturia Drugs estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Mixed Nocturia, one of the segments analyzed in the report, is projected to record a 6.1% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Low Nocturnal Bladder Capacity segment is readjusted to a revised 6.4% CAGR for the next 7-year period.
The Nocturia Drugs market in the U.S. is estimated at US$829.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$747.9 Million by the year 2027 trailing a CAGR of 5.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 4.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.
In the global Nocturnal Polyuria segment, USA, Canada, Japan, China and Europe will drive the 6.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$238 Million in the year 2020 will reach a projected size of US$375.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$490 Million by the year 2027.
SELECT PLAYERS
AA Pharma Inc.; Allergan PLC; Avadel Pharmaceuticals PLC; Ferring Pharmaceuticals; Glenmark Pharmaceuticals Ltd.; Teva Pharmaceutical Industries Ltd.; Urigen Pharmaceuticals, Inc.
SEGMENTS
» Drug Type (Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drug Types) » Indication (Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Nocturia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Nocturia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Nocturia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Mixed Nocturia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Mixed Nocturia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Mixed Nocturia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Low Nocturnal Bladder Capacity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Low Nocturnal Bladder Capacity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Low Nocturnal Bladder Capacity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Nocturnal Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Nocturnal Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Nocturnal Polyuria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Global Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Global Polyuria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Global Polyuria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Anticholinergic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Anticholinergic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Anticholinergic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Desmopressin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Antispasmodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Antispasmodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Antispasmodic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Nocturia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Nocturia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Nocturia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Nocturia Drugs by Indication - Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Nocturia Drugs by Indication - Percentage Breakdown of Value Sales for Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria and Global Polyuria for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Nocturia Drugs by Drug Type - Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Nocturia Drugs by Drug Type - Percentage Breakdown of Value Sales for Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic and Other Drug Types for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 38 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com